LOS ANGELES, March 19, 2018 /PRNewswire/ — CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the year ended December 31, 2017, and provided an overview of recent accomplishments and…



Source link